Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Helsinn and Mei Pharma have discontinued the Phase 3 trial that was investigating the safety and efficacy of a combination therapy of pracinostat and Vidaza (azacitidine) in newly-diagnosed patients with ... Read more
When given alongside Vidaza (azacitidine), Venclexta (venetoclax) elicits clinically meaningful responses and prolongs survival in untreated acute myeloid leukemia (AML) patients who are not eligible for intense chemotherapy, a Phase 3 ... Read more
The U.S. Food and Drug Administration (FDA) has agreed to Immune-Onc Therapeutics launching a Phase 1 clinical trial of IO-202, its lead antibody treatment candidate, in patients with advanced acute myeloid leukemia ... Read more
Roche has removed idasanutlin (RG7388), an investigational anti-cancer agent, from its Phase 3 MIRROS trial that was assessing the effectiveness of the medication when used in combination with chemotherapy in ... Read more
GT Biopharma has successfully completed dosing of the first patient participating in its Phase 1/2 clinical trial of GTB-3550 (OXS-3550), the company’s experimental treatment for relapsed or refractory acute myeloid ... Read more
APVO436, an investigational therapy for acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS), is showing safety and evidence of clinical activity in these patients, according to preliminary data from a ... Read more